Anti-Epileptic Drugs and Hormonal Treatments
Tóm tắt
Epilepsy and the medications used in its treatment are known to affect the menstrual cycle, aspects of contraception, and bone health in women. Adolescence is an important time to review the diagnosis of both epilepsy and the epilepsy syndrome because of the implications and decisions, which should be made regarding antiepileptic drug (AED) treatment. In girls, once they are on AED therapy, seizure free, and driving, it becomes difficult to change therapy because of the risk of breakthrough seizures and the fact that the new AED may not be as effective as the first. So a treatment choice made in adolescence is often life-long. Therefore, women need to be started on an AED that currently appears to be the most suitable for their seizure type, has a low teratogenic risk, and hopefully does not interact with contraception. There are no contraindications to the use of non-hormonal methods of contraception in women with epilepsy. Nonenzyme-inducing AEDs (valproate, benzodiazepines, ethosuximide, levetiracetam, tiagabine, and zonisamide) do not show any interactions with the combined oral contraceptive. There are interactions between the combined oral contraceptive and hepatic microsomal-inducing AEDs (phenytoin, barbiturates, carbamazepine, topiramate [dosages >200 mg/day], oxcarbazepine, eslicarbazepine and perampanel [dosages >12 mg/day]) and lamotrigine. Women taking enzyme inducing AEDs should be encouraged to use a method of contraception that is unaffected by their epilepsy medication. Interactions between AEDs and other hormonal therapies are less well studied. Studies have suggested that women with epilepsy are at increased risk of fractures, osteoporosis, and osteomalacia. No studies have been undertaken looking at preventative therapies for these comorbidities. This article will concentrate on current contraceptive treatment options in patients taking AEDs.
Tài liệu tham khảo
Moreau C, Trussell J, Rodriguez G, et al. Contraceptive failure rates in France: results from a population-based survey. J Hum Reprod. 2007;22(9):2422–7.
Brodie MJ, Mintzer S, Pack AM, et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11–27. An interesting review considering the potential clinical implications of the hepatic enzyme inducing effects of anti-epileptic drugs.
Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10:446–56.
Brodie MJ, Kwan P. Newer drugs for focal epilepsy in adults. BMJ. 2012;344:e345. Review of the newer drugs used for the treatment of epilepsy.
Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Statement. Update on newer antiepileptic and antiretroviral drugs and interactions with hormonal contraceptives. 2013. Available at: http://www.fsrh.org/pdfs/CEUstatementUpdateNewerAntiepilepticAntiretroviralDrugs.pdf Accessed December 21, 2013. Updated hormonal contraceptive guidelines detailing potential interactions with newer anti-epileptic drugs.
Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48:484–9.
Sabers A, Öhman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570–1.
Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia. 2005;46(9):342–8.
Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol. 2006;61:191–9.
Galimberti CA, Mazzucchelli I, Arbazino C, et al. Increased apparent oral clearance of valproate acid during intake of combined contraceptive steroids in women with epilepsy. Epilepsia. 2006;47:1569–72.
Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in antiepileptic patients. Br J Pharmacol. 1984;11:533–9.
Tomson T, Svensson J, Hilton-Brown P. Relationship of inter-individual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit. 1989;11:533–9.
Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate likelihood of metabolic pharmacodynamic interactions. Clin Pharmacokinet. 1997;32:210–58.
Wright SA, Stevens JC. The human hepatic cytochromes 450 involved in drug metabolism. Crit Rev Toxicol. 1992;22:1–21.
Levy RH. Cytochrome P450 isoenzymes and antiepileptic drug interactions. Epilepsia. 1995;36 Suppl 5:S8–S13.
Levy RH, Bishop F, Streeter AJ. Explanation and prediction of drug interactions with topiramate using CYP450 inhibition spectrum. Epilepsia. 1995;36 Suppl 4:47–51.
Davis AR, Westhoff CL, Stanczyk FZ. Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation and bleeding. Epilepsia. 2011;52(2):243–7.
Giuliano RA, Hiersemenzel E, Baltes G. Influence of a new antiepileptic drug (Levetiracetam, ucbLO59) on the pharmacokinetics and pharmacodynamics of oral contraceptives. Epilepsia. 1996;37 Suppl 4:90.
Eldon MA, Underwood BA, Randinitis EJ, et al. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology. 1998;50:1146–8.
Bockbrader HN, Posvar EL, Hunt T. Pharmacokinetics of pregabalin and a concomitantly administered oral contraceptive shows no drug-drug interaction. Epilepsia. 2004;45 Suppl 3:153.
Bartoli A, Gatti G, Cipolla G, et al. A double-blind placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia. 1997;38:702–7.
Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med. 1994;4:141–50.
Griffith SG, Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin Ther. 2004;12:2056–65.
Nakasa H, Nakamura H, Ono S, et al. Prediction of drug-drug interactions of zonisamide in humans from in vitro data. Eur J Clin Pharmacol. 1998; 54(2):177--83.
Cawello W, Rosenkranz B, Schmid B, et al. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. Epilepsia. 2013;54(3):530–6.
Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptives. Contraception. 1986;33:23–9.
Crawford P, Chadwick D, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol. 1990;30:892–6.
Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16:263–72.
Back DJ, Bates M, Bowden A, et al. The interactions of phenobarbital and other anticonvulsants with oral contraceptive therapy. Contraception. 1980;22:495–503.
Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Epilepsia. 1998;39:1226–31.
Guillebaud J. Drug interactions with hormonal contraception. J Fam Plan Reprod Health Care. 2005;31:335–6.
Marsh M, Kumar U. Practical recommendations for contraception. In: Panayiatopolis CP, Crawford PM, Thomson T, editors. Educational kit on epilepsies, vol 4, epilepsy and women. Oxford: Medicinae; 2008. p. 96–104.
Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. Clinical guidance: drug interactions with hormonal contraception. 2011. Available at: http://www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf Accessed December 21, 2013. Hormonal contraceptive guidelines detailing potential interactions with anti-epileptic drugs.
Betts T, Crawford P. Women and epilepsy. London: Martin Dunitz; 1998.
O’Brien M, Guillebaud J. Contraception for women with epilepsy. Epilepsia. 2006;47(9):1419–22.
Pharmacia Limited. Depo-Provera 150 mg/mL injection: Summary of Product Characteristics (SPC). 2007. Available at: http://www.medicines.org.uk/emc Accessed December 22, 2013.
Walsh JS, Eastell R, Peel NF. Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab. 2008;93:1317–23.
Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant therapy. Contraception. 1986;33:559–65.
Schindlbeck C, Janni W, Friese K. Failure of Implanon contraception in a patient taking carbamazepine for epilepsy. Arch Gynecol Obstet. 2006;273:255–6.
HRA Pharma UK Ltd. ellaOne: Summary of Product Characteristics. 2010. Available at: http://www.medicines.org/emc Accessed December 21, 2013.
Bounds W, Guillebaud J. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plan Reprod Health Care. 2002;28:78–80.